Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Jan 14, 2022; 10(2): 448-457
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.448
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Global N6-methyladenine DNA level in peripheral blood samples from 179 Alzheimer’s disease patients and 147 normal controls. AD: Alzheimer’s disease; NC: Normal control.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Relationship between leukocyte N6-methyladenine DNA levels and Alzheimer’s disease through dot blotting. Ten Alzheimer’s disease patients who were positron emission tomography (PET) positive and ten normal controls who were PET negative were age- and sex-matched. There were significant differences between the two groups, which indicated that the leukocyte N6-methyladenine DNA levels were different (P = 0.005; < 0.05, n = 10 people per group). MoCA: Montreal Cognitive Assessment.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Leukocyte N6-methyladenine DNA level is associated with Montreal Cognitive Assessment score. We analyzed the correlation between the Montreal Cognitive Assessment score and peripheral blood m6A levels and found that there was a significant correlation between the two in the tested population (r = 0.143, P = 0.01; < 0.05). NC: Normal control; AD: Alzheimer’s disease.